A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid

Journal of Medical Genetics

Volumn 34, Issue 9, 1997, Pages 758-760

  Smith, C A D ^a,c,d   Wadelius, Mia ^b   Gough, Alan C ^c   Harrison, D J ^d   Wolf, C Roland ^a   Rane, Anders ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Arylamine; Genotype; Isoniazid; N acetyltransferase; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ACETYLATOR PHENOTYPE; ARTICLE; CARCINOGENESIS; CAUCASIAN; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LUPUS ERYTHEMATOSUS; MUTATION; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0030885096     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.34.9.758     Document Type: Article

References (17)

1. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993;3:45-50.
2. Franke S, Klawitz I, Schnakenberg E, et al. Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochem Biophys Res Commun 1994;199:52-5.
3. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994;297:441-5.
4. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
5. Blum M, Grant DM, McBride W, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990;9:193-203.
6. Deguchi T. Physiology and molecular biology of arylamine N-acetyl transferases. Biomed Res 1992;13:231-42.
7. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
8. Hickman D, Sim E. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-14.
9. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992;2:217-26.
10. Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem 1995;231:413-20.
11. Svensson JO, Muchtar A, Eriksson O. Ion-pair high-performance liquid chromatographic determination of isoniazid and acetylisoniazid in plasma and urine. J Chromatogr 1985;341:193-7.
12. Smith CAD, Moss JE, Gough AC, et al. Molecular genetic analysis of the cytochromc P450 debrisoquine hydroxylase locus and association with cancer susceptibility. Env Health Persp 1992;98:107-12.
13. Martínez C, Agúndez JAG, Olivera M, et al. Lung cancer and mutations at the polymorphic NAT2 gene locus. Pharmacogenetics 1995;5:207-14.
14. Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
15. Graf T, Broly F, Hoffmann F, et al. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992;43:399-403.
16. Bechtel YC, Bonaiti-Pellie C, Poisson N, et al. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993;54:134-41.
17. Rothman N, Hayes RB, Bi W, et al. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993;3:250-5.